valproic acid has been researched along with Glycogen Storage Disease Type V in 2 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Glycogen Storage Disease Type V: Glycogenosis due to muscle phosphorylase deficiency. Characterized by painful cramps following sustained exercise.
| Excerpt | Relevance | Reference |
|---|---|---|
| "McArdle disease, also termed 'glycogen storage disease type V', is a disorder of skeletal muscle carbohydrate metabolism caused by inherited deficiency of the muscle-specific isoform of glycogen phosphorylase (GP-MM)." | 3.81 | Sodium valproate increases the brain isoform of glycogen phosphorylase: looking for a compensation mechanism in McArdle disease using a mouse primary skeletal-muscle culture in vitro. ( Andreu, AL; Arenas, J; Brull, A; de Luna, N; Guiu, JM; Lucia, A; Martí, R; Martin, MA; Pinós, T, 2015) |
| "McArdle disease is due to an absence of the enzyme muscle glycogen phosphorylase and results in significant physical impairment in humans." | 1.42 | Investigating sodium valproate as a treatment for McArdle disease in sheep. ( Creed, KE; Dunton, E; Howell, JM; Quinlivan, R; Sewry, C, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Howell, JM | 1 |
| Dunton, E | 1 |
| Creed, KE | 1 |
| Quinlivan, R | 1 |
| Sewry, C | 1 |
| de Luna, N | 1 |
| Brull, A | 1 |
| Guiu, JM | 1 |
| Lucia, A | 1 |
| Martin, MA | 1 |
| Arenas, J | 1 |
| Martí, R | 1 |
| Andreu, AL | 1 |
| Pinós, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Pilot Study to Explore Treatment With Sodium Valproate in Adults With McArdle Disease (Glycogen Storage Disorder Type V, GSDV)[NCT03112889] | Phase 2 | 8 participants (Anticipated) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for valproic acid and Glycogen Storage Disease Type V
| Article | Year |
|---|---|
Investigating sodium valproate as a treatment for McArdle disease in sheep.
Topics: Animals; Aspartate Aminotransferases; Calcium; Creatine Kinase; Disease Models, Animal; Drug Adminis | 2015 |
Sodium valproate increases the brain isoform of glycogen phosphorylase: looking for a compensation mechanism in McArdle disease using a mouse primary skeletal-muscle culture in vitro.
Topics: Animals; Brain; Cells, Cultured; Glycogen; Glycogen Phosphorylase; Glycogen Storage Disease Type V; | 2015 |